Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC)

Study Type – Therapy (RCT) Level of Evidence 1b

[1]  J Alfred Witjes,et al.  The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. , 2004, European urology.

[2]  P. Bendahl,et al.  Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. , 2009, European urology.

[3]  J. Witjes,et al.  Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. , 2005, The Journal of urology.

[4]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[5]  S. Lerner,et al.  Risk‐adapted use of intravesical chemotherapy , 2008, BJU international.

[6]  D. Lamm,et al.  Long-term results of intravesical therapy for superficial bladder cancer. , 1992, The Urologic clinics of North America.

[7]  P. Malmström,et al.  Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin‐C and bacillus Calmette‐Guérin in patients with high‐risk bladder cancer , 2007, BJU international.

[8]  A. Böhle,et al.  Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. , 2009, European urology.

[9]  R. Greenberg,et al.  Intravesical therapy for superficial bladder cancer. , 2000, Oncology.

[10]  M. Babjuk,et al.  Reply to Anna Orsola, Lluís Cecchini and Juan Morote's Letter to the Editor re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303–14 , 2009 .

[11]  L. Kiemeney,et al.  Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. , 1998, Urology.

[12]  P. Rigatti,et al.  A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. , 1995, The Journal of urology.

[13]  T S Herman,et al.  Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. , 1988, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[14]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[15]  A. Bohle.  Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study , 2010 .

[16]  O. Nativ,et al.  Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Salonia,et al.  Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Ed,et al.  Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.

[19]  Luc Bijnens,et al.  A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer , 1996 .

[20]  O. Nativ,et al.  Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. , 2011, Urologic oncology.

[21]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[22]  U. Nseyo,et al.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. , 1995, The Journal of urology.

[23]  L. Kiemeney,et al.  Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. , 2004, European urology.

[24]  A. Bohle,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[25]  K. Koshiba,et al.  Transurethral Resection of Bladder Tumor , 1979 .

[26]  J. Witjes,et al.  Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. , 2004, Urology.

[27]  W. Fair,et al.  The treated natural history of high risk superficial bladder cancer: 15-year outcome. , 1997, The Journal of urology.

[28]  C. Hulsbergen - van de Kaa,et al.  The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis , 2007, World Journal of Urology.

[29]  E. Crawford,et al.  Complications of intravesical chemotherapy. , 1992, The Urologic clinics of North America.

[30]  J. Witjes,et al.  Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. , 2008, European urology.